

 IIB

Calendar No. _____

115TH CONGRESS
2D SESSION

H. R. 1660

IN THE SENATE OF THE UNITED STATES

JANUARY 19, 2018

Received; read twice and referred to the Committee on Foreign Relations

_____ (legislative day, _____), _____

Reported by Mr. CORKER, without amendment

AN ACT

To direct the Administrator of the United States Agency for International Development to submit to Congress a report on the development and use of global health innovations in the programs, projects, and activities of the Agency.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Global Health Innova-
5 tion Act of 2017”.

1 **SEC. 2. ANNUAL REPORT.**

2 (a) IN GENERAL.—Not later than 180 days after the
3 date of the enactment of this Act, and annually thereafter
4 for a period of 4 years, the Administrator of the United
5 States Agency for International Development shall submit
6 to Congress a report on the development and use of global
7 health innovations in the programs, projects, and activities
8 of the Agency.

9 (b) MATTERS TO BE INCLUDED.—The report re-
10 quired by subsection (a) shall include the following:

11 (1) A description of—

12 (A) the extent to which global health inno-
13 vations described in subsection (a) include
14 drugs, diagnostics, devices, vaccines, electronic
15 and mobile health technologies, and related be-
16 havior change and service delivery innovations;

17 (B) how innovation has advanced the
18 Agency's commitments to achieving an HIV/
19 AIDS-free generation, ending preventable child
20 and maternal deaths, and protecting commu-
21 nities from infectious diseases, as well as
22 furthered by the Global Health Strategic
23 Framework;

24 (C) how goals are set for health product
25 development in relation to the Agency's health-

1 related goals and how progress and impact are
2 measured towards those goals;

3 (D) how the Agency's investments in inno-
4 vation relate to its stated goals; and

5 (E) progress made towards health product
6 development goals.

7 (2) How the Agency, both independently and
8 with partners, donors, and public-private partner-
9 ships, is—

10 (A) leveraging United States investments
11 to achieve greater impact in health innovation;

12 (B) engaging in activities to develop, ad-
13 vance, and introduce affordable, available, and
14 appropriate global health products; and

15 (C) scaling up appropriate health innova-
16 tions in the development pipeline.

17 (3) A description of collaboration and coordina-
18 tion with other Federal departments and agencies,
19 including the Centers for Disease Control and Pre-
20 vention, in support of global health product develop-
21 ment, including a description of how the Agency is
22 working to ensure critical gaps in product develop-
23 ment for global health are being filled.

24 (4) A description of how the Agency is coordi-
25 nating and aligning global health innovation activi-

1 ties between the Global Development Lab, the Cen-
2 ter for Accelerating Innovation and Impact, and the
3 Bureau for Global Health.